Carbimazole, Thiamazole (Methimazole)

Atresia of bile ducts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8483
R27824		 Yoshihara (Controls exposed to PTU), 2021 Biliary tract abnormality 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 24.02 [0.47;1238.43] C
excluded (control group) 		0/23   0/541 0 23
ref
S8482
R27802		 Yoshihara (Controls unexposed, sick), 2021 Biliary tract abnormality 1st trimester retrospective cohort unexposed, sick Adjustment: No 7.01 [0.28;177.06] C 0/23   1/475 1 23
ref
S3353
R5993		 Yoshihara (control exposed to PTU), 2012 Biliary atresia 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 3.41 [0.14;83.85] C
excluded (control group) 		1/1,231   0/1,399 1 1,231
ref
S3350
R5856		 Yoshihara (control unexposed, sick), 2012 Biliary atresia 1st trimester retrospective cohort unexposed, sick Adjustment: No 1.55 [0.10;24.79] C 1/1,231   1/1,906 2 1,231
ref
Total 2 studies 2.94 [0.36;24.10] 3 1,254
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Yoshihara (Controls unexposed, sick), 2021Yoshihara, 2021 1 7.01[0.28; 177.06]12342%ROB confusion: criticalROB selection: moderateROB classification: unclearROB missing: unclearROB mesure: criticalROB reporting: moderate Yoshihara (control unexposed, sick), 2012Yoshihara, 2012 2 1.55[0.10; 24.79]21,23158%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Total (2 studies) I2 = 0% 2.94[0.36; 24.10]31,2540.520.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: control unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.94[0.36; 24.10]31,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 2.94[0.36; 24.10]31,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 2 Tags Adjustment   - No  - No 2.94[0.36; 24.10]31,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 2 All studiesAll studies 2.94[0.36; 24.10]31,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3353, 8483

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 2.94[0.36; 24.10]31,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 7.41[0.62; 88.97]11,2540%NAYoshihara (Controls exposed to PTU), 2021 Yoshihara (control exposed to PTU), 2012 20.510.01.0